arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Q32 Bio Inc.

QTTB
$15.61 ▼ -0.55 (-3.43%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
10 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
69
Health
Good
Bullish
auto_awesome

Analytical Summary

Q32 Bio Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $192.0M
Dividend Yield
Revenue Growth None
Op. Margin 31.5%
ROIC 31.8%
FCF / Share $-2.73
Trailing P/E 6.5x
Price / Book 4.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$53.74M
Net Income Profit after all expenses
$29.82M
↑ +162.5%
Operating Margin Operating profit as % of sales
31.5%
↑ +111.1% 87th
FCF / Share Free cash flow per share
$-2.73
↑ +62.5%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
63
Returns
98
Cash Quality
10

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 38 quarters